EGFR and prostate carcinoma: This positive feedback was observed in both early (PNT2‐ETV1 cells) and advanced (LNCaP cells) models of ETV1‐driven oncogenic activity, while a link with ERG was not observed in the corresponding ERG‐positive cell models (PNT2‐ERG and VCaP cells), sustaining the potential efficacy of EGFR inhibitors for the treatment of ETV1‐positive prostate carcinomas.